Adenovirus-retrovirus hybrid vectors achieve highly enhanced tumor transduction and antitumor efficacy in vivo.
Murine leukemia virus (MLV)-based replication-competent retrovirus (RCR) vectors have been shown to mediate efficient, selective, and persistent tumor transduction, thereby achieving significant therapeutic benefit in a wide variety of cancer models. To further augment the efficiency of this strategy, we have developed a delivery method employing a gutted adenovirus encoding an RCR vector (AdRCR); thus, tumor cells transduced with the adenoviral vector transiently become RCR vector producer cells in situ. As expected, high-titer AdRCR achieved significantly higher initial transduction levels in human cancer cells both in vitro and in vivo, as compared to the original RCR vector itself. Notably, even at equivalent initial transduction levels, more secondary RCR progeny were produced from AdRCR-transduced cells as compared to RCR-transduced cells, resulting in further acceleration of subsequent RCR replication kinetics. In pre-established tumor models in vivo, prodrug activator gene therapy with high-titer AdRCR could achieve enhanced efficacy compared to RCR alone, in a dose-dependent manner. Thus, AdRCR hybrid vectors offer the advantages of high production titers characteristic of adenovirus and secondary production of RCR in situ, which not only accelerates subsequent vector spread and progressive tumor transduction, but can also significantly enhance the therapeutic efficacy of RCR-mediated prodrug activator gene therapy.
Kubo
Shuji
S
Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan. s-kubo@hyo-med.ac.jp
Haga
Kazunori
K
Tamamoto
Atsuko
A
Palmer
Donna J
DJ
Ng
Philip
P
Okamura
Haruki
H
Kasahara
Noriyuki
N
D000818:Animals; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics*; D006367:HeLa Cells; D006801:Humans; D009052:Leukemia Virus, Murine / Q000235:genetics / Q000502:physiology*; D051379:Mice; D008819:Mice, Nude; D009369:Neoplasms / Q000235:genetics / Q000628:therapy* / Q000821:virology*; D050130:Oncolytic Virotherapy / Q000379:methods*; D012190:Retroviridae / Q000235:genetics / Q000502:physiology*; D014161:Transduction, Genetic; D014183:Transplantation, Heterologous; D014779:Virus Replication / Q000235:genetics
Gene Ther. 2008 Jun;15(12):877-84
18418413
Neurosurg Focus. 2006 Apr 15;20(4):E25
16709031
Mol Ther. 2003 Nov;8(5):846-52
14599819
J Gene Med. 2004 Feb;6 Suppl 1:S164-71
14978759
J Virol. 1999 Dec;73(12):10426-39
10559361
Hum Gene Ther. 2001 May 20;12(8):921-32
11387057
J Gene Med. 2005 Mar;7(3):276-87
15515136
J Gen Virol. 1977 Jul;36(1):59-74
886304
J Virol. 2002 Dec;76(24):12783-91
12438603
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5731-6
8650161
Hum Gene Ther. 2001 Jul 20;12(11):1417-28
11485633
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4511-8
17671137
J Virol. 2007 Jul;81(13):6973-83
17442710
Curr Gene Ther. 2007 Jun;7(3):189-204
17584037
Curr Gene Ther. 2004 Mar;4(1):1-14
15032610
Front Biosci. 2008 Jan 01;13:3083-95
17981778
Methods Mol Biol. 2004;246:499-525
14970613
Cancer Gene Ther. 2007 Mar;14(3):279-86
17218950
Cancer Res. 2007 Jun 1;67(11):5345-53
17545615
Mol Ther. 2007 Mar;15(3):457-66
17245356
Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1002-7
10655474
Methods Mol Biol. 2008;433:33-53
18679616
Hum Gene Ther. 1997 Jan 1;8(1):65-71
8989996
J Clin Oncol. 2003 Jul 1;21(13):2508-18
12839017
Hum Gene Ther. 2010 Jan;21(1):40-50
19725756
Mol Ther. 2002 May;5(5 Pt 1):599-608
11991751
J Virol. 2006 Jul;80(14):7070-8
16809312
J Virol. 2003 Mar;77(5):2964-71
12584321
Virology. 2002 Feb 15;293(2):328-34
11886253
Cancer Gene Ther. 2003 Jan;10(1):30-9
12489026
Proc Natl Acad Sci U S A. 2006 May 23;103(21):8036-41
16698926
Clin Cancer Res. 2006 Dec 1;12(23):7108-16
17145835
Gene Ther. 2006 Oct;13(20):1457-70
16724095
Curr Gene Ther. 2005 Dec;5(6):655-67
16457654
Hum Gene Ther. 2003 Jan 20;14(2):117-27
12614563
Nat Biotechnol. 2001 Jun;19(6):582-5
11385466
Mol Ther. 2005 Nov;12(5):842-51
16257382
EMBO J. 1996 Apr 15;15(8):1766-77
8617221
Methods Mol Med. 2003;76:343-52
12526173
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):7866-71
9653106
Mol Ther. 2001 May;3(5 Pt 1):809-15
11356086